









市场行情
/
股票
/
nasdaq-cai
/

Caris Life Sciences Inc

CAI

27.940USD

+0.080+0.29%

收盘 12/19, 16:00（美东）报价延迟15分钟

7.88B总市值

亏损市盈率 TTM



Caris Life Sciences Inc

27.940

+0.080+0.29%

概览公司财务分析

概览

公司

财务

分析

关于 Caris Life Sciences Inc 公司

Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

Caris Life Sciences Inc简介



公司代码CAI

公司名称Caris Life Sciences Inc

上市日期Jun 18, 2025

CEOHalbert (David Dean)

员工数量- -

证券类型Ordinary Share

年结日Jun 18

公司地址750 W. John Carpenter Freeway

城市IRVING

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编75039

电话18667718946

网址https://www.carislifesciences.com/

公司代码CAI

上市日期Jun 18, 2025

CEOHalbert (David Dean)

Caris Life Sciences Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. George H. Poste, Ph.D.

Vice Chairman of the Board

511.70K

-2.76%

Mr. Luke Power

Chief Financial Officer, Senior Vice President, Chief Accounting Officer

99.57K

Mr. David (Dave) Fredrickson

Independent Director

16.13K

Mr. Nathan Burns

Independent Director

Mr. Vijay Mohan

Independent Director

Mr. Danny Phillips

Independent Director

Dr. Lloyd B. Minor, M.D.

Independent Director

Mr. Peter M. Castleman

Lead Independent Director

J. Russel Denton

Senior Vice President, General Counsel, Secretary

Dr. Jeffrey L. (Jeff) Vacirca, M.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. George H. Poste, Ph.D.

Vice Chairman of the Board

511.70K

-2.76%

Mr. Luke Power

Chief Financial Officer, Senior Vice President, Chief Accounting Officer

99.57K

Mr. David (Dave) Fredrickson

Independent Director

16.13K

Mr. Nathan Burns

Independent Director

Mr. Vijay Mohan

Independent Director

Mr. Danny Phillips

Independent Director

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

178.18M

98.22%

International

3.22M

1.78%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Halbert (David D)

43.51%

Sixth Street Partners, LLC

8.64%

J.H. Whitney Capital Partners, LLC

7.18%

Castleman Peter M

3.68%

Coatue Management, L.L.C.

3.59%

其他

33.40%

持股股东

占比

Halbert (David D)

43.51%

Sixth Street Partners, LLC

8.64%

J.H. Whitney Capital Partners, LLC

7.18%

Castleman Peter M

3.68%

Coatue Management, L.L.C.

3.59%

其他

33.40%

股东类型

持股股东

占比

Individual Investor

48.47%

Investment Advisor

20.21%

Hedge Fund

11.05%

Private Equity

10.52%

Investment Advisor/Hedge Fund

4.85%

Pension Fund

0.53%

Research Firm

0.29%

Sovereign Wealth Fund

0.13%

Bank and Trust

0.08%

其他

3.86%

机构持股



更新时间: 7月2日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

172

130.04M

46.09%

+127.36M

2025Q2

192.42M

69.23%

+189.87M

2025Q1

2.55M

0.92%

+2.55M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Halbert (David D)

122.76M

43.65%

-141.96K

-0.12%

Aug 11, 2025

Sixth Street Partners, LLC

24.39M

8.67%

+24.39M

Jun 30, 2025

J.H. Whitney Capital Partners, LLC

20.26M

7.2%

+20.26M

Jun 30, 2025

Castleman Peter M

10.37M

3.69%

+10.34M

+32049.87%

Jun 18, 2025

Coatue Management, L.L.C.

10.14M

3.61%

+10.14M

Jun 30, 2025

Fidelity Management & Research Company LLC

8.61M

3.06%

+8.61M

Jun 30, 2025

T. Rowe Price Investment Management, Inc.

7.30M

2.6%

+7.30M

Jun 30, 2025

Braidwell LP

7.32M

2.6%

+7.32M

Jun 30, 2025

T. Rowe Price Associates, Inc.

6.76M

2.4%

+6.76M

Jun 30, 2025

Silver Lake Partners

5.29M

1.88%

+5.29M

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

ARK Genomic Revolution ETF

0.67%

Texas Capital Texas Small Cap Equity Index ETF

0.52%

Renaissance IPO ETF

0.43%

RiverNorth Patriot ETF

0.3%

Franklin Genomic Advancements ETF

0.29%

Invesco Russell 1000 Equal Weight ETF

0.08%

Inspire 500 ETF

0.07%

T Rowe Price Small-Mid Cap ETF

0.05%

Texas Capital Texas Equity Index ETF

0.04%

Fidelity Nasdaq Composite Index ETF

0.02%

ARK Genomic Revolution ETF

占比0.67%

Texas Capital Texas Small Cap Equity Index ETF

占比0.52%

Renaissance IPO ETF

占比0.43%

RiverNorth Patriot ETF

占比0.3%

Franklin Genomic Advancements ETF

占比0.29%

Invesco Russell 1000 Equal Weight ETF

占比0.08%

Inspire 500 ETF

占比0.07%

T Rowe Price Small-Mid Cap ETF

占比0.05%

Texas Capital Texas Equity Index ETF

占比0.04%

Fidelity Nasdaq Composite Index ETF

占比0.02%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Caris Life Sciences Inc的前五大股东是谁？



Caris Life Sciences Inc 的前五大股东如下：
Halbert (David D)持有股份：122.76M，占总股份比例：43.65%。
Sixth Street Partners, LLC持有股份：24.39M，占总股份比例：8.67%。
J.H. Whitney Capital Partners, LLC持有股份：20.26M，占总股份比例：7.20%。
Castleman Peter M持有股份：10.37M，占总股份比例：3.69%。
Coatue Management, L.L.C.持有股份：10.14M，占总股份比例：3.61%。